Compare MUC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUC | HELP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 889.9M |
| IPO Year | 1997 | 2020 |
| Metric | MUC | HELP |
|---|---|---|
| Price | $10.49 | $11.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 369.2K | ★ 1.8M |
| Earning Date | 01-01-0001 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.20 | $3.76 |
| 52 Week High | $11.16 | $14.35 |
| Indicator | MUC | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 32.59 | 56.69 |
| Support Level | $10.20 | $4.41 |
| Resistance Level | $10.85 | $14.35 |
| Average True Range (ATR) | 0.08 | 0.75 |
| MACD | -0.01 | -0.26 |
| Stochastic Oscillator | 5.61 | 24.53 |
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes. The fund mainly invests in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and California personal income taxes. Under normal market conditions, it invests a majority of its managed assets in investment-grade municipal obligations with remaining maturities of one year or more at the time of investment. It can also invest in below investment-grade securities, or directly in such securities or synthetically through the use of derivatives.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.